Fluvoxamine, melatonin and COVID-19.
作者信息
Anderson George M
机构信息
Child Study Center and the Department of Laboratory Medicine, Yale University School of Medicine, 230 S. Frontage Rd., New Haven, CT, 06525, USA.
出版信息
Psychopharmacology (Berl). 2021 Feb;238(2):611. doi: 10.1007/s00213-020-05753-z. Epub 2021 Jan 4.
Abstract
摘要
相似文献
1
Fluvoxamine, melatonin and COVID-19.
Psychopharmacology (Berl). 2021 Feb;238(2):611. doi: 10.1007/s00213-020-05753-z. Epub 2021 Jan 4.
2
COVID-19 Infection-Preventing Clinical Deterioration.
JAMA. 2020 Dec 8;324(22):2300. doi: 10.1001/jama.2020.21720.
3
Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?
Pharmacopsychiatry. 2021 May;54(3):142-143. doi: 10.1055/a-1408-8298. Epub 2021 Mar 17.
4
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
5
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
6
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
J Infect Public Health. 2023 Dec;16(12):2010-2016. doi: 10.1016/j.jiph.2023.10.010. Epub 2023 Oct 6.
7
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
8
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
JAMA. 2023 Dec 26;330(24):2354-2363. doi: 10.1001/jama.2023.23363.
9
Fluvoxamine for the treatment of COVID-19.
Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391. doi: 10.1002/14651858.CD015391.
10
Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19.
Cell Stress Chaperones. 2022 Jan;27(1):3-4. doi: 10.1007/s12192-021-01246-w. Epub 2021 Nov 30.
引用本文的文献
1
Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches.
Life (Basel). 2025 Mar 11;15(3):439. doi: 10.3390/life15030439.
2
Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: a retrospective cohort study using real-world data.
Lancet Reg Health West Pac. 2023 May;34:100716. doi: 10.1016/j.lanwpc.2023.100716. Epub 2023 Feb 27.
3
The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis.
Health Sci Rep. 2022 Oct 17;5(6):e892. doi: 10.1002/hsr2.892. eCollection 2022 Nov.
4
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.
CNS Drugs. 2022 Jul;36(7):681-702. doi: 10.1007/s40263-022-00931-3. Epub 2022 Jun 21.
5
Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
6
Sleep Dysfunction in COVID-19 Patients: Prevalence, Risk Factors, Mechanisms, and Management.
J Pers Med. 2021 Nov 14;11(11):1203. doi: 10.3390/jpm11111203.
7
Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder.
J Psychiatr Res. 2022 May;149:367-373. doi: 10.1016/j.jpsychires.2021.11.025. Epub 2021 Nov 17.
8
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.
Br J Clin Pharmacol. 2022 May;88(5):2065-2073. doi: 10.1111/bcp.15126. Epub 2021 Dec 1.
9
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
10
Recent advances in management of COVID-19: A review.
Biomed Pharmacother. 2021 Nov;143:112107. doi: 10.1016/j.biopha.2021.112107. Epub 2021 Aug 27.
本文引用的文献
1
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
Zotero 插件